Cevimeline
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Cevimeline is an orally administered muscarinic receptor agonist that is indicated for the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Several well designed placebo-controlled trials demonstrated that 4-12 weeks' therapy with cevimeline 30 mg three times daily improved symptoms of dry mouth in patients with Sjogren's syndrome. Other symptoms, such as dry eye symptoms and overall dryness, also improved to a significantly greater extent with cevimeline than with placebo. Moreover, cevimeline significantly improved the salivary flow rate in patients with Sjogren's syndrome. Increased salivary flow was maintained in the longer term with cevimeline in patients with Sjogren's syndrome and symptoms of dry mouth, according to the results of an open-label 52-week study. From week 20 onwards, rates of patient and investigator satisfaction with the cevimeline dosage were > or =88%. Oral cevimeline 30 mg three times daily was generally well tolerated in patients with Sjogren's syndrome, with many of the most commonly reported adverse events reflecting the pharmacological action of the drug.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cevimeline hydrochloride is a cholinergic agonist that increases glandular secretion and is indicated in the treatment of xerostomia in patients with SjS [5].”
From Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report (2022) · cites this paper as [5]
In the citing paper
“The drug acts by binding and activating M3 receptors, resulting in increased secretions from exocrine glands, including the salivary and sweat glands [5].”
From Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report (2022) · cites this paper as [5]
Citations
Cites
Fox, R. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66990-5 · Cited by 1,828
Petrone, D., Condemi, J. J., Fife, R., Gluck, O., Cohen, S., & Dalgin, P. (2002) · Arthritis & Rheumatism · doi:10.1002/art.510 · Cited by 282
Cevimeline for the Treatment of Xerostomia in Patients With Sjögren Syndrome: A Randomized Trial
Fife, R. S., Chase, W. F., Dore, R. K., Wiesenhutter, C. W., Lockhart, P. B., Tindall, E., & Suen, J. Y. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.11.1293 · Cited by 193
The management of Sjögren's syndrome
Mavragani, C. P., Moutsopoulos, N. M., & Moutsopoulos, H. Μ. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0165 · Cited by 127
Xerostomia Secondary to Sj??gren???s Syndrome in the Elderly: Recognition and Management
Al‐Hashimi, I. H. (2005) · Drugs & Aging · doi:10.2165/00002512-200522110-00001 · Cited by 71
Conventional Therapy of Sjogren’s Syndrome
Mavragani, C. P., & Moutsopoulos, H. Μ. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8008-3 · Cited by 67
Leung, K., McMillan, A. S., Wong, M. C. M., Leung, W. K., Mok, M. Y., & Lau, C. S. (2007) · Clinical Rheumatology · doi:10.1007/s10067-007-0723-x · Cited by 63
Iwabuchi, Y., & Masuhara, T. (1994) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(94)90021-3 · Cited by 58
A review and update of Sjögren's syndrome: manifestations, diagnosis, and treatment.
Carsons, S. (2001) · PubMed · Cited by 57
Iga, Y., Arisawa, H., Ogane, N., Saito, Y., Tomizuka, T., Nakagawa-Yagi, Y., Masunaga, H., Yasuda, H., & Miyata, N. (1998) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.78.373 · Cited by 48
Research works printed but not linked: 5
- Ohtani, 1990, Rinsho Iyaku, 6, 1551
- Kashiwazaki, 2001, Shinryo To Shinyaku, 38, 393
- Kashiwazaki, 2001, Shinryo To Shinyaku, 38, 333
- Ichikawa, 2001, Shinryo To Shinyaku, 38, 349
- Ichikawa, 2001, Shinryo To Shinyaku, 38, 369
Cited by
Diagnosis and management of xerostomia and hyposalivation
Villa, A., Connell, C., & Abati, S. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s76282 · Cited by 452
Salivary Secretory Disorders, Inducing Drugs, and Clinical Management
Miranda-Rius, J., Brunet-Llobet, L., Lahor-Soler, E., & Farré, M. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.12912 · Cited by 187
Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity
Halder, N., & Lal, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660342 · Cited by 180
van der Putten, G.-J., Brand, H. S., Schols, J. M. G. A., & Baat, C. D. (2010) · Clinical Oral Investigations · doi:10.1007/s00784-010-0382-1 · Cited by 184
Villa, A., Wolff, Ä., Aframian, D. J., Vissink, A., Ekström, J., Proctor, G., McGowan, R., Narayana, N., Aliko, A., Sia, Y. W., et al. (2015) · Clinical Oral Investigations · doi:10.1007/s00784-015-1488-2 · Cited by 159
Metadata
- Authors
- Weber, J., & Keating, G. M.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Keating, Gillian M
- Venue
- Drugs
- Published
- 2008
- Volume
- 68
- Issue
- 12
- Pages
- 1691-1698
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W3192301371
- Cited by
- 33
- References
- 25
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 1 · 2012: 1
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Salivary Gland Disorders and Functions
- Health Sciences › Medicine › Ophthalmology › Ocular Surface and Contact Lens
- Health Sciences › Dentistry › General Dentistry › HIV/AIDS oral health manifestations
- Keywords
- cevimeline, Sjögren's syndrome, xerostomia, muscarinic agonists, salivary flow rate, dry eye symptoms, drug tolerability, adverse events, patient satisfaction
- MeSH terms
- Animals, Diarrhea, Female, Half-Life, Humans, Nausea, Quinuclidines, Rhinitis, Sjogren's Syndrome, Sweating, Thiophenes, Molecular Structure, Randomized Controlled Trials as Topic, Treatment Outcome, Muscarinic Agonists, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cevimeline. https://app.cochat.ai/papers/10.2165/00003495-200868120-00006
- The paper
- Weber, J., & Keating, G. M. (2008). Cevimeline. Drugs. https://doi.org/10.2165/00003495-200868120-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.